Novartis and Transposagen-backed gene and cell therapy developer Poseida Therapeutics closed the series D round two days after filing to go public.
Poseida Therapeutics, a US-based gene therapy developer backed by pharmaceutical firm Novartis, completed a $110m series D round on Thursday led by funds advised by investment and financial services group Fidelity.
Adage Capital Management, Schonfeld Strategic Advisors and unnamed existing shareholders also took part in the round, which closed just two days after Poseida filed for a $115m initial public offering on the Nasdaq Global Select Market.
Founded in 2014, Poseida is developing gene engineering technologies intended to form…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
